Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Agios today played a few of the cards it plans to show the FDA later this year when it files for an approval of its IDH1 drug ivosidenib.
Just a few months since the FDA handed out an OK for the IDH2 drug Idhifa, which Celgene largely controls, Agios $AGIO says in its ASH abstract that the first group of 125 patients in their pivotal study of acute myeloid leukemia demonstrated a complete response rate of 21.6%, with 8.8% seeing a CR with partial hematologic recovery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.